Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020

Fabien Taieb (1) , Khardiata Diallo Mbaye (2) , Billo Tall (1) , Ndèye Aïssatou Lakhe (2) , Cheikh Talla (1) , Daouda Thioub (2) , Amadou Moustapha Ndoye (1) , Daye Ka (2) , Aboubacry Gaye (1) , Viviane Marie-Pierre Cissé Diallo (2) , Ndongo Dia (1) , Pape Samba Ba (3) , Mamadou Cissé (1) , Moustapha Diop (3) , Cheikh Tidiane Diagne (1) , Louise Fortes (2, 4) , Mamadou Diop (3) , Ndèye Maguette Fall (2, 5) , Fatoumata Diène Sarr (1) , Margarite Diatta (1) , Mamadou Aliou Barry (1) , Aboubakar Sidikh Badiane (2) , Abdoulaye Seck (1) , Philippe Dubrous (1) , Ousmane Faye (1) , Inès Vigan‑womas (1) , Cheikh Loucoubar (1) , Amadou Alpha Sall (1) , Moussa Seydi (1)

1 Institut Pasteur de Dakar
2 CHNU Fann
3 Hôpital Principal de Dakar
4 CHNDJ - Centre Hospitalier National Dalal Jamm
5 UFR-Santé Thiès, Hôpital pour Enfants de Diamniadio

As of today, little data is available on COVID-19 in African countries, where the case management relied mainly on a treatment by association between hydroxychloroquine (HCQ) and azithromycin (AZM). This study aimed to understand the main clinical outcomes of COVID-19 hospitalized patients in Senegal from March to October 20202. We described the clinical characteristics of patients and analysed clinical status (alive and discharged versus hospitalized or died) at 15 days after Isolation and Treatment Centres (ITC) admission among adult patients who received HCQ plus AZM and those who did not receive this combination. A total of 926 patients were included in this analysis. Six hundred seventy-four (674) (72.8%) patients received a combination of HCQ and AZM. Results showed that the proportion of patient discharge at D15 was significantly higher for patients receiving HCQ plus AZM (OR: 1.63, IC 95% (1.09–2.43)). Factors associated with a lower proportion of patients discharged alive were: age ≥ 60 years (OR: 0.55, IC 95% (0.36–0.83)), having of at least one pre-existing disorder (OR: 0.61, IC 95% (0.42–0.90)), and a high clinical risk at admission following NEWS score (OR: 0.49, IC 95% (0.28–0.83)). Few side effects were reported including 2 cases of cardiac rhythmic disorders in the HCQ and AZM group versus 13 in without HCQ + AZM. An improvement of clinical status at 15 days was found for patients exposed to HCQ plus AZM combination

Mots clés: SARS-CoV-2; hydroxychloroquine; azithromycin; treatment; Senegal

Domaines: Microbiologie et Parasitologie; Immunologie; Biologie cellulaire; Biologie moléculaire; Santé publique et épidémiologie

Fabien Taieb, Khardiata Diallo Mbaye, Billo Tall, Ndèye Aïssatou Lakhe, Cheikh Talla, et al.. Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. Journal of Clinical Medicine, 2021, Special Issue Global Public Health in COVID-19: Pandemic Research from University Hospital Institute Méditerranée Infection, 10 (13), pp.2954. ⟨10.3390/jcm10132954⟩. ⟨pasteur-03506532⟩